Home \ Antibodies \ C3d, Human, clone HB2C2
Catalog # HM2422

C3d, Human, clone HB2C2

Antibody clone #HB2C2 recognizes a neo-epitope of complement C3dg. The antibody does not recognize C3 or (i)C3b

Read more
Please choose the quantity of items you wish to add to your cart…
Find distributor

Antibody clone #HB2C2 recognizes a neo-epitope of complement C3dg. The antibody does not recognize C3 or (i)C3b The complement system plays important roles in both innate and adaptive immune response and can produce an inflammatory and protective reaction to challenges from pathogens before an adaptive response can occur.

It consists of a complex family of proteins and receptors which are found in the circulation, in tissues and other body-fluids. There are three pathways of complement activation. The classical pathway is initiated by Immune complexes; the lectin pathway by surface bound lectins; and the AP by all the surfaces that are not specifically protected against it. Each generates a C3 convertase, a serine protease that cleaves the central complement protein C3, and generates the major cleavage fragment C3b. The C3 and C5 convertases are enzymatic complexes that initiate and amplify the activity of the complement pathways and ultimately generate the cytolytic MAC. The synthesis of C3 is tissue-specific and is modulated in response to a variety of stimulatory agents. After cleavage by C3 convertase the anaphylotoxin C3a and activating C3b are formed.

When bound to the cell surface C3b forms the start of the terminal pathway of complement by initiating the formation of the C5 convertase. Further cleavage of C3b by trypsinlike enzymes lead to formation of iC3b and subsequently C3c and C3dg. The latter digested to leave C3d. The formation of C3dg into C3d in blood is a slow step. As a result the majority will be C3dg.C3 has a molecular weight of app. 185kDa and is the most abundant protein of the complement system with serum protein levels of about 1.3 mg/ml. C3dg is a non-glycosylated single chain protein of 38.9 KDa. Most assays cannot distinguish between the different C3 proteins. C3 activation products are involved in a number of diseases like transplantation rejection, kidney diseases, AMD and inflammatory diseases. Surface bound C3 proteins also have role, eg via complement receptor2 (CR2), in regulating the adaptive immune response.

Therefor complement fragments serve as biomarkers for many of these diseases. The binding of C3dg to the cell membrane is rather unstable, leading to release of the protein. As end product of C3 activation, this makes it an attractive diagnostic biomarker. Instead of C3 &C4 it reflects more ongoing complement activation. Most antibodies, although recognizing an epitope on the C3d part of the alpha chain, do not differentiate between the native and activated C3 proteins.

Immuno assays, Immuno fluorescence, Western blot

Application Notes
20 µg/ml

Product type
Monoclonal antibodies
100 µg, 20 µg
0.2ug filtered in PBS +0.02%NaN3+0.1%BSA
Cross reactivity
Mouse – Yes
Mouse IgG1
For research use only. Not for use in or on humans or animals or for diagnostics. It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product.
Autoimmunity, Infectious diseases, Nephrology, Neurological disorders
Storage and stability
Product should be stored at 4°C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.
CoA-TDS Safety Data Sheet

You may be interested in…

Calculate your ELISA data easily

With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.

Latest Hycult Biotech news

  • New Human Complement Pathway Assays
    We are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
  • Navigating the pitfalls in complement analysis
    Our colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
  • NEW Human C3d ELISA
    We are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA
Contact us